Roche's oral SERD giredestrant misses first-line breast cancer target

Roche’s phase 3 persevERA trial of the oral SERD giredestrant in first-line ER-positive, HER2-negative locally advanced or metastatic breast cancer did not meet its primary endpoint, showing no statistically significant progression-free survival benefit versus letrozole plus Ibrance (though a numerical improvement was noted). Adverse events were manageable, and Roche plans to pursue FDA filing based on second-line and adjuvant data while continuing the pionERA trial in endocrine-resistant disease. The setback adds cautiousness to the outlook for oral SERDs in first-line settings and prompts analysts to temper earlier multi-billion-dollar sales expectations.